These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1978511)

  • 1. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.
    Goldstein M; Lieberman AN; Takasugi N; Shimizu Y; Kuga S
    Adv Neurol; 1990; 53():101-6. PubMed ID: 1978511
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine agonists, sleep disorders, and driving in Parkinson's disease.
    Uitti RJ; Wszolek ZK
    Adv Neurol; 2003; 91():343-9. PubMed ID: 12442692
    [No Abstract]   [Full Text] [Related]  

  • 4. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 5. Early dopamine agonist therapy in Parkinson's disease.
    Rinne UK
    Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915
    [No Abstract]   [Full Text] [Related]  

  • 6. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 7. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological basis of therapeutics: dopamine receptors.
    Heikkila RE
    J Med Soc N J; 1984 Dec; 81(12):1084-6. PubMed ID: 6150999
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG; Fahn S; Lovelle S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J; Bustos JC; Magariños C; Martinez A
    Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F
    Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522
    [No Abstract]   [Full Text] [Related]  

  • 11. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA
    Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of dopamine receptors in neurological drug treatment.
    Rinne UK
    Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905
    [No Abstract]   [Full Text] [Related]  

  • 18. Progress in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Jan; 15(1):1. PubMed ID: 18171385
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.